alexa Gene Mutation Status in Glioblastoma

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Gene Mutation Status in Glioblastoma

Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults [1]. Although GBM occurs in patients of all ages, the incidence is highest in the elderly, and GBM is slightly more common in whites and men [1,2]. Astrocytic tumors are the most common glial neoplasms, with an annual incidence of 3-4/100,000 inhabitants, and approximately 80% are glioblastomas [3]. In India the incidence is about 3/100,000 population [4]. In Kashmir (North India), among the brain tumors glioma (60%) is the commonest in which GBM is the most common followed by diffuse and anaplastic astrocytoma [5]. Glioblastomas remain one of the most lethal forms of cancers with a median survival of 10 to 12 months [6]. Unlike most other types of cancer, glioblastomas rarely metastasize; rather, they induce death through striking resistance to current therapies and invasion into normal brain tissues [7]. Recent therapies in GBM have focused on the inhibition of tyrosine kinases and associated growth factor pathways. Over activity of the epidermal growth factor receptor (EGFR) pathway is associated with resistance to treatment with RT and chemotherapy [8,9]. Therefore, combining targeted EGFR therapy with RT or chemotherapy may increase the effectiveness of treatment.

Citation: Arif SH, Pandith AA, Bhat AR, Ramzan AU, Malik Nk,et al. (2015) EGFR and PTEN Gene Mutation Status in Glioblastoma Patients and their Prognostic Impact on Patient’s Survival. J Carcinog Mutagen 6:218. doi: 10.4172/2157-2518.1000218

 
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger